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1723-61 Hemodynamic Effects of Graded Oral Doses of a New
Dopaminergic Analogue CHF 1035 In Patients with
Congestive Heart Failure
lACC February 1995
5 mg 10 mg 15 mg
PD AD PD AD PD AD
PCWP 22 ± 5 18 ± 4* 20 ± 6 16 ± 9* 21 ± 7 16 ± 6*
CI 3± 1 3.4 ± 1* 2.7 ± 1 3.4 ± 1* 3±1 4 ± 1*
SVI 39 ± 12 43 ± 11 38± 7 45 ± 10* 40± 10 49 ± 11*
SVR 1243 ± 27 1052 ± 265 1382 ± 45 1009±315 1359 ± 36 881 ± 257*
HR 74 ± 11 78 ± 11* 70 ± 11 76 ± 12 74 ± 12 80 ± 10*
8Pm 85 ± 12 82 ± 12 85 ± 10 77 ± 13* 87 ± 11 79 ± 12*
NE 299 ± 135 301±156 285 ± 244 244 ± 88* 340 ± 162 308 ± 133
E 56 ± 29 42 ± 21* 65 ± 42 62 ±44 53 ± 25 58 ± 24
*: p < 005
No changes in hemodynamic or neurohormonal parameters occurred af-
ter P administration. Our results demonstrate that CHF 1035 induce a signifi-
cant improvement in hemodynamic parameters in pts with CHF. In particular
it is able to induce systemic vasodilatation without any reflex increase in cate-
cholamine plasma levels. Thus CHF 1035 appears to be a promising drug for
the treatment of CHF.
Transcatheter treatment of atrioventricular nodal reentrant tachycardia
(AVNRT) modifies but frequently does not eliminate the electrophysiologic
substrate for reentry. The extent of modification required thus remains un-
clear. High recurrence rates have been reported when single AV nodal echos
(AVNe) remain inducible. We, therefore, prospectively evaluated the charac-
teristics of AVNe pre and postAV nodal modification.
Results: Ablation was deemed successful when sustained AVNRT could
not be induced on isoproternol (ISO). After successful ablation, AVNe was in-
ducible in 24 pts and noninducible in 72 pts. Other electrophysiologic param-
eters in these two groups were comparable with similar increases in 1: 1 AV
block cycle lengths (356 to 413 and 368 to 400 msec, p < 0.005) and AVNERP
(258 to 317 and 264 to 313 msec, p < 0.001) pre to post ablation. In Group 1
patients, persistent AVNes following successful ablation (good echoes) were
associated with an increase in AH interval in all but one patient as compared
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Electrophysiologic Endpoints of Successful
Radlofrequency Catheter Modification for
Atrioventricular Nodal Reentrant Tachycardia. Are
There "Good" and "Bad" Persistent Echoes?
Anwer Dhala. Zalmen Blanck, Margaret Budziszewski, Michael Biehl,
Sanjay Deshpande, Jasbir Sra, Mohammad R. Jazayeri, Masood Akhtar. Sinai
Samaritan/St. Luke'5 Medical Center, Milwaukee, WI
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1724-1 1Characteristics of Successful Posterior Septal Sites
to Cure Atrioventricular Node Reentry Using a
Thermistor Controlled Catheter System
Rafe Chamberlain Webber, John N. Hill, Joseph J. Evans, Richard I. Fogel, Eric
N. Prystowsky. Indiana Heart Institute, Indianapolis, IN
We prospectively investigated in 55 pts characteristics of successful radiofre-
quency ablation (RFA) sites to cure AVN reentry (AVNRT) using a thermistor
tipped catheter system with a posterior (slow pathway) approach. RFA suc-
cess (SI was :0:2 AVNRT echos after RFA; only 1 pt had AVNRT at follow-up.
There were 166 RFA [55 S; 111 failure (F)], with 3 ± 3/pt. Local atrial electro-
gram morphology was-A (low to isoelectric to high frequency); B (low to
high frequency); and C (:::2 high frequency components). Differences with S
vs F, respectively. are: atrial amplitude (396 ± 181 vs 357 ± 205 /Lv' P < 0.001);
ventricular amp. (3.0 ± 1.6 vs 2.7 ± 1.6 mV, p < 0.001); time to onset of junc-
tional tachycardia (JT) (2.1 ± 1.9 vs 4.6 ± 6.1 sec, p < 0.05); duration of JT
1146 ± 8.6 vs 11.6± 7.7 sec, p < 0.001); CL ofJT(481 ± 92vs 511 ± 120
ms, p < 0.0011; and change in CL of JT during RFA (-34 ± 113 vs +23 ± 128
ms, p < 0.03). Of note, continuous JT was more common at S sites (46% vs
21 %), and JT occurred in :0:7.5 sec at all S sites. No differences between Svs
F were in: power(46.8 ± 7.5 vs 44.5 ± 8.6 W); catheter tip temp. (52.6 ± 4.6
vs 49.3 ± 5.5"C); atrial electrogram duration (66 ± 20 vs 66 ± 19 ms); ortype
of local atrial electrogram. We conclude: 11 Successful RFA to cure AVNRT
more frequently occurs with rapid onset of continuous junctional tachycardia
with a CL that shortens before termination and, 2) there is no specific local
atrial electrogram morphology that predicts success.
ABSTRACfS
ther effect. There was a 16 msec increase in the PR interval at rest with 2 mg
(159 to 175 msec, P < 0.01) with no further change at 5 mg. The increase in
PR persisted even during peak exercise (115, 134 & 149 msec with placebo.
2 &5 mg, P < 0.001). The drug had no effect on resting &exercise blood
pressure, exercise time, V02, anaerobic threshold, ventilatory indices, and
epinephrine, norepinephrine or aldosterone at peak exercise. However. SDZ
WAG 994 completely suppressed the normal increase in plasma renin activ-
ity(PRA) with exercise (P < 0.01). An interesting and unexpected finding was
a dose-dependent increase in ANF seen both at rest and peak exercise (P <
0.01). These findings suggest that a single dose of this oral adenosine A, se-
lective agonist, has the expected negative chronotropic &dromotropic prop-
erties in man, even during exercise when circulating catecholamines were
very high (epinephrine 299 ± 220 pg/ml, norepinephrine 1947 ± 998 pg/ml)
without any adverse cardiovascular effects. Its effects on PRA &ANF suggest
that SDZ WAG 994 may also be an important neurohormonal modulator in
man.
Carmine Morisco, Bruno Ricciardelli, Luigi Argenziano, Virgilio Rendina,
Guido laccarino, Carmine Vecchione, Alberto Umile 1, Massimo Volpe
Bruno Trimarco. I Clinica Medica Universita "FEDERICO II" Napoli, Italy; i Chiesi
Farmaceutici s.p.A., Italy
We investigated in a randomized double-blind study the hemodynamic ef-
fects of 3 single oral doses (5, 10 and 15 mg) of a new dopaminergic ana-
logue (CHF 1035) VS placebo (P) in 18 patients (pts) with congestive hea rt fail-
ure (CH F) (ejection fraction 25 ± 7%). Each patient received on 3 consecutive
study-days 2 active doses of CHF 1035 and 1 Pdose. The following measure-
ments were performed using a Swan-Ganz catheter pre-dose (PO) and from
20 to 300 min after dosing (AD) levery 20 min for the first 2 hours, then ev-
ery 60 min): pulmonary capillary wedge pressure (PCWP) (mmHg), cardiac
index ICI) (I/min/m2), stroke volume index (ml/min/m2), systemic vascular re-
sistance (SVR) (dyne. sec· cm-5), heart rate (HR) Ibpm). mean blood pressure
(BPm) (mmHg). Plasma levels of norepinephrine (NE) (pg/ml) and epinephrine
(E) (pg/ml) were also assessed before and 140 min after CHF 1035 or P ad-
ministration. The hemodynamic (peak value) and neurohormonal parameters
showed the following changes after CHF 1035 administration.
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Evaluation of the Antianginal and Anti·ischemic
Effects of the Sinus Node Inhibitor Zatebradine Used
in Combination with Extended·Release Nifedipine In
Patients with Angina Pectoris
William Frishman, Carl Pepine, Robert WeiSS, Wolfgang Baiker, Zatebradine
Multicenter Study Group. Albert Einstein College ofMedicine, Bronx, NY
Zatebradine (Z) is a directsinus node inhibitor which is orally active and, unlike
p-adrenergic blockers, has no effect on blood pressure, vascular resistances,
and ventricular contractility. We evaluated the anginal and anti-ischemic ef-
fects of Z 15 mg administered twice daily) and placebo in 124 patients (pts)
already receiving 3D-90 mg of extended-release nifedipine once daily, whose
treadmill exercise tolerance was still limited. After 2-3 wks of single-blind
placebo therapy with reproducible exercise-induced angina on the treadmill,
pts were randomized to receive in double-blind fashion twice daily Z (n = 64)
or twice daily placebo (n = 60) in addition to nifedipine. Subjects were fol-
lowed with serial exercise tests 13 hrs post dose) for 4 wks and angina diaries
were maintained. At 4 wks, Z was shown to reduce resting heart rate (HR) in
contrast to placebo (12.9 ± 1,23 vs 2.3 ± 1.6 bpm, p < 0.0001), and at the
end of comparable stages of exercise (Bruce). Z reduced HR in contrast to
placebo (16.7 ± 1.2 vs 3.4 ± 1.2 bpm, p < 0.001). Despite these significant
effects on HR with Z at rest and exercise, there were no additional antiang-
inal benefits of Z from placebo baseline in measurements of total exercise
duration, time to 1 mm ST segment depression, or time to onset of angina.
Z appears to provide no additional antianginal benefit to pts already receiving
nifedipine, and raises questions regarding the benefit of HR reduction alone
as an antianginal approach in pts.
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